Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (457)	5/18/1999 7:31:00 AM
From: SemiBull	Read Replies (1) \| Respond to of 712

From Jim Jubak Piece Posted Today: (http://moneycentral.msn.com/articles/invest/jubak/3225.asp) "Updates New Developments on Past Columns 7 top biotech picks for 1999 The seven stocks in my biotechnology portfolio haven't exactly torn up the track this year -- the portfolio of five September picks and two March 1999 picks was up 3.2% for the year to date as of May 17 (you can get the full list by clicking on the headline above). But there's been good news recently from COR Therapeutics (CORR) and Ligand Pharmaceuticals (LGND). On April 20, COR Therapeutics reported first-quarter sales of Integrilin, the company's drug for treating unstable angina and myocardial infarction and for use in angioplasty patients, of $11 million, about $2 million above estimates. Sales are currently running at a pace of about $1 million a week and the company has upped estimates of Integrilin sales to $200 million for 2000. Ligand recently announced that in pre-clinical studies, its drug Targretin, used in combination with tamoxifen, caused a complete or partial regression in 94% of primary breast tumors that had shown resistance to tamoxifen alone. Results from the company's ongoing Phase 2 study of Targretin are expected in the second half of 1999. I continue to recommend both stocks at recent prices."